Budapest, Hungary, October 04, 2016 / B3C newswire / -- Argint International (“Argint”), a European clinical research organisation specialised in providing services to small and medium sized pharmaceutical and biotech companies, have been ranked as a top 10 CRO by members of the Pharma IQ community. Pharma IQ, a division of IQPC, is an international online community focusing on providing pharmaceutical professionals with knowledge, information and articles.
The voting base was 100,000 members of the Pharma IQ network, made up of participants from big pharma, SME pharma and solution providers. When choosing a CRO, quality of services was seen as the most important factor of Pharma IQ members, closely followed by reputation and level of experience. Agnes Pinnel, CEO of Argint International commented “Argint is extremely pleased to be recognised by our clients and industry peers for the quality of our services. We would like to thank everyone who voted for us. This recognition is really for the people who have worked for Argint over the years and helped Argint develop into a CRO that our clients can rely upon.”
About Argint International
Argint International Clinical Research and Development Services (Argint) is a privately owned CRO, providing clinical research services throughout Europe. Argint is focused on providing tailor made full-service solutions to small and medium sized biotech companies, partnering clients as they bring their drug candidates or devices into the clinical phase. Argint supports the planning and execution of our client’s development programs: from initial consultancy through phase I, POC and larger phase II and phase III studies.
